CI
Cigna
$282.08
▲ 1.0%Updated Today 7:15 PM ET
▼ Down 11.2% over the last 12 months
Market Cap
$73.88B
P/E
11.74x
Forward P/E (est.)
9x
ROE
15.2%
Revenue Growth
8.8%
EPS Growth
30.5%
Profit Margin
2.3%
FCF Yield
9.7%
Debt / Equity
0.75x
ROIC
9.0%
Interest Coverage
—
Current Ratio
0.82x
Dividend Yield
2.1%
Implied Growth (rev. DCF)
—
Rating Score
60/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CI's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CI trades near $282.08, around its 50-day average ($283.71) and 200-day average ($281.52). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 51 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. CI's is $6.95 (~2.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CI found buyers near $270.43 (support) and sellers near $299.27 (resistance); its 52-week range is $239.51–$338.89. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Cigna (CI) is a large-cap company in the Health Care Services industry, part of the Health Care sector of the S&P 500, with a market value around $73.88B.
In its latest reported year it generated about $274.90B in revenue and $5.96B in net profit.
Our model rates CI Favorable (60/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
12.1%
Revenue moved from $174.07B in 2021 to $274.90B in 2025, a 12.1% compound annual growth rate. The most recent year grew a steady 8.8% year over year. Slower, mature growth is common for established businesses.
Gross Margin
9.2%
Operating Margin
3.3%
Net Margin
2.2%
ROE
15.2%
Cigna keeps about 2.3% of each sales dollar as net profit, with a 9.2% gross margin and 3.3% operating margin. Return on equity is 15.2% and return on invested capital about 9.0%. Thin margins leave less cushion if costs rise.
Total Debt
$39.52B
Net Debt
$32.48B
Net Debt / EBITDA
3.53x
Debt / Equity
0.75x
Leverage: debt-to-equity is 0.8x, with a current ratio of 0.8x. That is a moderate, manageable debt load for most businesses. It carries roughly $39.52B of total debt against $7.04B of cash.
Operating CF
$9.60B
Free Cash Flow
$9.60B
FCF Margin
3.5%
In the latest year Cigna produced about $9.60B of operating cash flow and $9.60B of free cash flow after capital spending. That is a free-cash-flow yield of about 9.7% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
11.74x
P/S
0.28x
P/B
1.69x
EV / EBITDA
9.16x
CI trades at 11.7x trailing earnings (about 9.0x on estimated forward earnings), 0.3x sales, and 1.7x book value. That is an undemanding multiple — potentially cheap if the business is stable.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How CI stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), CI ranks #19 of 59 by our overall rating. It trades at a discount versus the sector on earnings (11.7x P/E vs. 25.4x median) with a higher return on equity (15.2% vs. 14.9%) and faster revenue growth (8.8% vs. 7.9%).
P/E vs sector
11.7x
median 25.4x
ROE vs sector
15.2%
median 14.9%
Growth vs sector
8.8%
median 7.9%
Sector rank
#19
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$335.77 – $575.61
vs. $282.08 today · expected CAGR 4% – 15%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $299.64B | $326.61B | $356.00B | $388.04B | $422.97B |
| Net income | $8.99B | $9.80B | $10.68B | $11.64B | $12.69B |
| EPS | $33.98 | $37.04 | $40.37 | $44.01 | $47.97 |
| Share price (low) | $237.87 | $259.28 | $282.61 | $308.05 | $335.77 |
| Share price (high) | $407.78 | $444.48 | $484.48 | $528.09 | $575.61 |
| CAGR (low–high) | -16% / 45% | -4% / 26% | 0% / 20% | 2% / 17% | 4% / 15% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CI:
- Strong return on equity (15.2%) shows capital is put to work well.
- Healthy free-cash-flow yield (~9.7%) funds buybacks and dividends.
- Pays a 2.1% dividend on top of any price gains.
- Our model's overall read is Favorable (60/100).
The case against CI:
- Thin net margins (2.3%) leave little room for error.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Margin risk — thin profitability (2.3%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Cigna is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 11.7x earnings, which our model scores Favorable (60/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.